Total Payments
$20,414
2024 Payments
$8,388
Companies
24
Transactions
111
Medicare Patients
593
Medicare Billing
$89,017
Payment Breakdown by Category
Consulting$17,241 (84.5%)
Food & Beverage$2,630 (12.9%)
Other$350.00 (1.7%)
Education$124.43 (0.6%)
Travel$68.64 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $17,241 | 9 | 84.5% |
| Food and Beverage | $2,630 | 95 | 12.9% |
| Grant | $350.00 | 1 | 1.7% |
| Education | $124.43 | 4 | 0.6% |
| Travel and Lodging | $68.64 | 2 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TerSera Therapeutics LLC | $3,125 | 3 | $0 (2024) |
| Gilead Sciences, Inc. | $2,869 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,733 | 12 | $0 (2024) |
| GE HealthCare | $2,616 | 1 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $2,466 | 6 | $0 (2024) |
| Seagen Inc. | $2,257 | 3 | $0 (2023) |
| Stemline Therapeutics Inc. | $1,477 | 3 | $0 (2023) |
| Daiichi Sankyo Inc. | $1,102 | 1 | $0 (2024) |
| PFIZER INC. | $379.96 | 23 | $0 (2019) |
| Bayer Healthcare Pharmaceuticals Inc. | $275.14 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,388 | 8 | TerSera Therapeutics LLC ($3,125) |
| 2023 | $3,960 | 9 | Seagen Inc. ($2,257) |
| 2022 | $6,084 | 3 | Gilead Sciences, Inc. ($2,700) |
| 2020 | $97.02 | 5 | Rigel Pharmaceuticals, Inc. ($24.22) |
| 2019 | $1,173 | 54 | PFIZER INC. ($317.25) |
| 2018 | $677.95 | 30 | Lilly USA, LLC ($151.34) |
| 2017 | $33.71 | 2 | BTG International, Inc. ($18.33) |
All Payment Transactions
111 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $108.95 | General |
| 12/02/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,102.00 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,340.00 | General |
| 10/23/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $95.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Travel and Lodging | Cash or cash equivalent | $29.79 | General |
| Category: Oncology | ||||||
| 07/02/2024 | AstraZeneca Pharmaceuticals LP | — | Grant | Cash or cash equivalent | $350.00 | General |
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Consulting Fee | Cash or cash equivalent | $2,362.50 | General |
| Category: Oncology | ||||||
| 12/22/2023 | Seagen Inc. | TUKYSA (Drug) | Consulting Fee | Cash or cash equivalent | $2,112.50 | General |
| Category: Oncology | ||||||
| 12/22/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $38.85 | General |
| Category: Oncology | ||||||
| 12/05/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $59.58 | General |
| Category: ONC | ||||||
| 11/16/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $105.23 | General |
| Category: Oncology | ||||||
| 09/29/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | Cash or cash equivalent | $1,240.00 | General |
| Category: Oncology | ||||||
| 08/17/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $92.74 | General |
| Category: Oncology | ||||||
| 06/05/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $144.75 | General |
| Category: Oncology | ||||||
| 05/22/2023 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $149.57 | General |
| Category: Oncology | ||||||
| 05/19/2023 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Oncology | ||||||
| 09/22/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $768.00 | General |
| Category: Oncology | ||||||
| 09/02/2022 | GE HealthCare | — | Consulting Fee | Cash or cash equivalent | $2,616.00 | General |
| 06/20/2022 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 03/06/2020 | Amgen Inc. | Neulasta (Biological) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: Oncology | ||||||
| 02/28/2020 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: Hematology | ||||||
| 01/31/2020 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: Oncology | ||||||
| 01/28/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: Oncology | ||||||
| 01/21/2020 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: HEMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 249 | 438 | $192,545 | $40,497 |
| 2022 | 7 | 274 | 443 | $189,274 | $40,313 |
| 2021 | 3 | 70 | 86 | $33,099 | $8,207 |
Total Patients
593
Total Services
967
Medicare Billing
$89,017
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 78 | 162 | $56,922 | $12,233 | 21.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 37 | 121 | $50,090 | $11,873 | 23.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 32 | 32 | $25,264 | $4,851 | 19.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 23 | 39 | $21,921 | $4,380 | 20.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 28 | $23,852 | $4,056 | 17.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 31 | 35 | $8,481 | $1,691 | 19.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 20 | 21 | $6,015 | $1,413 | 23.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 81 | 161 | $54,750 | $12,448 | 22.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 35 | 94 | $37,180 | $8,119 | 21.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 44 | $36,647 | $7,208 | 19.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 28 | 28 | $20,888 | $4,396 | 21.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 25 | 37 | $20,294 | $4,074 | 20.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 44 | 49 | $11,333 | $2,252 | 19.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 26 | 30 | $8,182 | $1,816 | 22.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 17 | 31 | $16,399 | $3,901 | 23.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 38 | 40 | $13,280 | $3,437 | 25.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 15 | 15 | $3,420 | $869.10 | 25.4% |
About Nan Chen
Nan Chen is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/06/2015. The National Provider Identifier (NPI) number assigned to this provider is 1558749887.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Nan Chen has received a total of $20,414 in payments from pharmaceutical and medical device companies, with $8,388 received in 2024. These payments were reported across 111 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($17,241).
As a Medicare-enrolled provider, Chen has provided services to 593 Medicare beneficiaries, totaling 967 services with total Medicare billing of $89,017. Data is available for 3 years (2021–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Chicago, IL
- Active Since 05/06/2015
- Last Updated 04/03/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1558749887
Products in Payments
- Zoladex (Drug) $3,125
- KISQALI (Drug) $2,363
- TUKYSA (Drug) $2,257
- Orserdu (Drug) $1,477
- ENHERTU (Biological) $768.00
- IMFINZI (Drug) $259.99
- Vitrakvi (Drug) $166.57
- ELIQUIS (Drug) $166.36
- CABLIVI (Drug) $120.94
- CYRAMZA (Drug) $106.43
- IBRANCE (Drug) $94.15
- EMPLICITI (Biological) $77.83
- VYXEOS (Drug) $67.97
- OPDIVO (Biological) $66.64
- Xofigo (Drug) $59.92
- Trodelvy (Drug) $59.58
- Tavalisse (Drug) $55.97
- CHANTIX (Drug) $52.40
- Nubeqa (Drug) $48.65
- Abraxane (Drug) $45.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678